Eye Movement Abnormalities in Major Depressive Disorder

Junichi Takahashi¹, Yoji Hirano¹,², Kenichiro Miura³, Kentaro Morita⁴,⁵, Michiko Fujimoto³,⁶, Hidenaga Yamamori⁵,⁶,⁷, Yuka Yasuda³,⁶, Noriko Kudo³,⁹, Emiko Shishido¹⁰, Kosuke Okazaki¹¹, Tomoko Shiino¹²,¹³, Tomohiro Nakao¹, Kyoto Kasai⁵,¹⁴, Ryota Hashimoto³,⁶ and Toshiaki Onitsuka¹⁰

¹ Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ² Institute of Industrial Science, The University of Tokyo, Tokyo, Japan, ³ Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan, ⁴ Department of Rehabilitation, The University of Tokyo Hospital, Tokyo, Japan, ⁵ Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁶ Department of Psychiatry, Graduate School of Medicine, Osaka University, Suita, Japan, ⁷ Japan Community Health Care Organization Osaka Hospital, Osaka, Japan, ⁸ Life Grow Brilliant Mental Clinic, Osaka, Japan, ⁹ Graduate School of Science and Technology, Nara Institute of Science and Technology, Ikoma, Japan, ¹⁰ Division of Cerebral Integration, Department of System Neuroscience, National Institute for Physiological Sciences, Okazaki, Japan, ¹¹ Department of Psychiatry, Nara Medical University, Kashihara, Japan, ¹² Division of Developmental Emotional Intelligence, Research Center for Child Mental Development, University of Fukui, Fukui, Japan, ¹³ United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Japan, ¹⁴ The International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced Study, Tokyo, Japan

Background: Despite their high lifetime prevalence, major depressive disorder (MDD) is often difficult to diagnose, and there is a need for useful biomarkers for the diagnosis of MDD. Eye movements are considered a non-invasive potential biomarker for the diagnosis of psychiatric disorders such as schizophrenia. However, eye movement deficits in MDD remain unclear. Thus, we evaluated detailed eye movement measurements to validate its usefulness as a biomarker in MDD.

Methods: Eye movements were recorded from 37 patients with MDD and 400 healthy controls (HCs) using the same system at five University hospitals. We administered free-viewing, fixation stability, and smooth pursuit tests, and obtained 35 eye movement measurements. We performed analyses of covariance with group as an independent variable and age as a covariate. In 4 out of 35 measurements with significant group-by-age interactions, we evaluated aging effects. Discriminant analysis and receiver operating characteristic (ROC) analysis were conducted.

Results: In the free-viewing test, scanpath length was significantly shorter in MDD (p = 4.2 × 10⁻³). In the smooth pursuit test, duration of saccades was significantly shorter and peak saccade velocity was significantly lower in MDD (p = 3.7 × 10⁻³, p = 3.9 × 10⁻³, respectively). In the fixation stability test, there were no significant group differences. There were significant group differences in the older cohort, but not in the younger cohort, for the number of fixations, duration of fixation, number of saccades, and fixation density in the free-viewing test. A discriminant analysis using scanpath length in the free-viewing test and peak saccade velocity in the smooth pursuit showed MDD could be distinguished from HCs with 72.1% accuracy. In the ROC analysis,
the area under the curve was 0.76 (standard error = 0.05, \( p = 1.2 \times 10^{-7} \), 95% confidence interval = 0.67–0.85).

**Conclusion:** These results suggest that detailed eye movement tests can assist in differentiating MDD from HCs, especially in older subjects.

**Keywords:** major depressive disorder, free-viewing test, fixation stability test and smooth pursuit test, alerting aging effect, discriminant analysis, eye movements

### INTRODUCTION

Major depressive disorder (MDD) is a common global disorder that affects over 264 million people (1). Depression is ranked as the single largest contributor to global disability (7.5% of all years lived with a disability) (2) and has been one of the top three leading causes of health loss for nearly three decades (3). The lifetime prevalence of MDD was reported to be 14–17% with a 1-year prevalence of 4–8% (WHO, 2020). Many studies have attempted to elucidate the pathophysiology of depression; however, it remains poorly understood. Stressful events, genetic vulnerability, environmental interactions, abnormalities in several neurotransmitters, inflammation, as well as alterations in neuropeptides and hormones have been investigated as causes of MDD (4–6). Natural disasters (7), pandemics such as COVID-19 (8–10), and cultural differences (11–14) also have a huge impact on the development of MDD.

Clinically, it is difficult to diagnose mood disorders in patients with MDD and bipolar disorder (15). For example, during the initial evaluation, patients with bipolar disorder sometimes show only depressive symptoms and thus receive antidepressants based on a diagnosis of MDD, which may cause several critical problems (16, 17). For this reason, objective indices for MDD are needed; however, to date, none have been established.

Eye movements are considered a potential biomarker for the diagnosis of mental illness (18, 19). We previously showed an integrated score using three measurements (scanpath length during a free-viewing test, horizontal position gain during the fast Lissajous paradigm in a smooth pursuit test, and the duration of fixations during the far distractor paradigm of a fixation stability test) could distinguish between patients with schizophrenia (SZ) and HCs with 82% accuracy (20). A recent review has provided convincing evidence of eye-movement abnormalities in SZ (21, 22). However, Smyrnis et al. (23) noted that the sensitivity of eye movement deficits to differentiate psychiatric patients from healthy controls (HCs) was not high enough to be clinically relevant for diagnostic purposes. In the previous study (20), our group reported that eye movement can be a useful biomarker for schizophrenia. In order to use eye movements as a diagnostic tool, it is necessary to discriminate schizophrenia from other psychiatric disorders. Therefore, we conducted the same tasks used in the previous studies.

As listed in **Table 1**, several studies have used different methods to evaluate eye movements in MDD. Iacono et al. (24) reported that the performance of the MDD group was not significantly different from that of the HC group regarding smooth-pursuit eye movement (SPEM), but smooth-pursuit tracing errors were greater for those with a higher frequency of episodes of the disorder. Abel et al. (25) studied smooth pursuit gain and catch-up saccade (CUS) in affective disorders and found that when the constant stimulus velocity was 5°/s, but not 20°/s, MDD patients had higher CUS rates than HCs. Malaspina et al. (26) studied the effects of electroconvulsive therapy (ECT) on SPEM with severe MDD and reported that SPEM was transiently disrupted but pursuit performances were improved after two sessions of ECT and at 2 months follow-up. They concluded that SPEM abnormalities may be a state marker in severe MDD. Flechtnet al. (27) explored SPEM in thirty-four MDD patients and found they exhibited lower pursuit gain and higher CUS rates than HCs. Flechtnet al. (28) also reported that SPEM performance was not influenced by medication or clinical state in a test-retest study. Fabisch et al. (29) reported no significant difference between unipolar depressed patients and HCs. Li et al. (31) reported that compared with the HC group, the MDD group had a significantly shorter duration and more saccades in a fixation stability test. Taken together, these studies indicate inconsistent findings regarding eye movement abnormalities in MDD.

In the present study, we recorded eye movements and determined the detailed characteristics of eye movements in MDD patients at multiple facilities. We then examined how eye movements might be useful for differentiating between MDD and HCs.

### MATERIALS AND METHODS

**Subjects**

Patients with MDD recruited from Kyushu University Hospital, Osaka University Hospital, The University of Tokyo Hospital, and Nagoya University Hospital were diagnosed by two or more trained psychiatrists according to criteria from the DSM-IV based on the Structured Clinical Interview for DSM-IV (SCID). All subjects were biologically unrelated, were of Japanese descent, and had no history of ophthalmologic disease, or neurological/medical conditions that might influence the central nervous system. Specific exclusion criteria included atypical headaches, head trauma with loss of consciousness, thyroid disease, epilepsy, seizures, substance-related disorders, or intellectual disability. HCs were recruited through regional advertisements and were evaluated for psychiatric, medical, and neurological concerns using the non-patient version of the SCID to exclude individuals with current or past contact with psychiatric services or who had received psychiatric medication. Eye movements were recorded...
### TABLE 1 | Demographic and clinical characteristics of the study subjects and major findings of patients with MDD in eight eye movement studies.

| Study                  | Task   | Age (years) Mean SD | Male N % | Currently on medication N % | Age (years) Mean SD | Male N % | Parameters | Major findings in MDD |
|------------------------|--------|---------------------|----------|-----------------------------|---------------------|----------|------------|-----------------------|
| Iacono et al. (24)     | SPEM   | 37.9 12.9           | 5 20     | N/A                         | 48 35.0 11.9        | 8 22.9   | RT, RMSE   | All variables: no significance |
| Abel et al. (25)       | SPEM   | 48.4 12.4           | 16 100   | 4 25                        | 21 37.5 10.9        | 21 100   | TWAG, CUS rates, CUS amplitude  |
| Malaspina et al. (26)  | SPEM   | 28.9 5.6            | N/A N/A  | 0 0                         | 20 30.6 7           | N/A N/A  | % abn, Large saccades | All variables: no significance |
| Flechtner et al. (27)  | SPEM   | 46.9 11             | 9 26.5   | 30 88.2                     | 42 34.3 10.9        | 20 47.6  | Pursuit gain, CUS, Lower pursuit gain, Anticipatory saccade, BUS, SWJ |
| Flechtner et al. (28)  | SPEM   | 46.9 11             | 9 26.5   | 34 100                      | 42 34.3 10.9        | 20 47.6  | Pursuit gain, CUS, All variables: no significant difference between all time |
| Fabisch et al. (29)    | SPEM   | 34.4 8.3            | 19 100   | 19 100                      | 21 37.8 5.9         | 21 100   | Peak gain, CUS error, CUS velocities | All variables: no significance |
| Chen et al. (30)       | FVT    | 28.3 4.7            | N/A N/A  | 0 0                         | 19 27.9 4.6         | N/A N/A  | NF, tFD, aFD | More NF, longer tFD and aFD |
| Li et al. (31)         | FST    | 25.4 7.2            | N/A N/A  | 0 0                         | 60 24.2 6.1         | N/A N/A  | NF, FD, Number of More NF and number of saccades, shorter FD, longer saccade path | Shorter duration of saccade path, Saccade saccade, longer amplitude, mFD, Saccade path |
|                        | FVT    |                     |          |                             |                     |          |            |                                      |

SPEM, Smooth pursuit eye movement; FVT, Free-viewing test; FST, Fixation stability test; RT, Reaction time; RMSE, Root mean square error; TWAG, Time-weight average gain; CUS, Catch-up saccade; BUS, Back-up saccade; SWJ, Square wave jerk; NF, number of fixations; tFD, total fixation duration; aFD, average fixation duration; FD, fixation duration; mFD, mean fixation duration.

*This study analyzed remitted MDD.

This study analyzed affective disorders (MDD non-psychotic = 10, MDD psychotic = 1, bipolar depression non-psychotic = 4, schizoaffective disorder = 1).

**A longitudinal study by Flechtner et al. (27):**
TABLE 2 | Demographics of the HC and MDD groups.

|                      | HCs       | MDD      | $\chi^2$ or $t$ | $p$-value |
|----------------------|-----------|----------|----------------|-----------|
| Male/female          | 201/199   | 18/19    | 0.04           | 0.85      |
| Age (years)          | 35.3 ± 14.8 | 49.5 ± 11.6 | $-7.0$            | $8.6 \times 10^{-9}$ |
| Education (years)    | 15.4 ± 2.3 | 14.5 ± 2.4 | 2.1            | 0.41      |
| Premorbid IQ         | 107.7 ± 8.1 | 106.9 ± 10.9 | 0.38          | 0.71      |
| Current IQ           | 107.1 ± 12.0 | 100.4 ± 13.5 | 2.7            | $6.7 \times 10^{-3}$ |
| Onset age (years)    | 36.9 ± 13.6 | 13.0 ± 8.4 | 13.5 ± 2.7    | 0.0005    |
| Duration of illness  |          |          | 12.0 ± 6.3     |           |
| HAM-D                |          |          | 187.9 ± 150.4  |           |
| IMP (mg)             |          |          | 6.0 ± 5.9      |           |
| DZP (mg)             |          |          | 61.9 ± 117.1   |           |

Premorbid IQ was estimated using the Japanese Adult Reading Test. 
Current IQ was estimated using the Wechsler Intelligence Scale short form.
HAM-D, Hamilton Depression Rating Scale; IMP, imipramine; DZP, diazepam; CPZ, chlorpromazine.

from 51 patients with MDD and 519 HCs, who were recruited from Kyushu University (28 MDD, 29 HCs), Osaka University (15 MDD, 333 HCs), The University of Tokyo (6 MDD, 70 HCs), Nagoya University (2 MDD, 48 HCs), and Nara Medical University (0 MDD, 40 HCs). Each facility used a common protocol and analysis manual, and quality control was performed every 2 months to ensure uniformity of the data. We used the data from 37 patients with MDD and 400 HCs, for which the quality of the data was ensured by rigorous quality checks. Current symptoms of depression were evaluated using the Hamilton Depression Scale (HAM-D) (32) and the total dosages of prescribed the antidepressant benzodiazepine or antipsychotics were calculated using imipramine (IMP), diazepam (DZP), and chlorpromazine (CPZ) equivalents (mg/day) (33). The demographic information of the study subjects is shown in Table 2. Based on the criteria for depression (34), 15 patients showed mild depression, 9 showed moderate depression, and 1 showed severe depression and 9 were euthymic. HAM-D scores of the three patients were unknown.

The study was performed in accordance with the World Medical Association’s Declaration of Helsinki and was approved by the Research Ethical Committees of Kyushu University, Osaka University, The University of Tokyo, Nagoya University, and Nara Medical University. All participants provided written consent to the study after a full explanation of the study procedures. Anonymity was preserved for all participants.

Eye Movement Recordings and Processing of Eye Movement Data

The subjects faced a 19-inch liquid crystal display monitor placed 70 cm from the observers’ eyes. Visual stimuli were presented using MATLAB (The Mathworks, Natick, MA, USA) via the Psychophysics Toolbox extension (35). The eye movements and pupil areas of the left eye were measured at 1 kHz using the EyeLink1000 Plus (SR Research, Ontario, Canada) system.

Eye position data were smoothed with a digital FIR filter (−3 dB at 30 Hz), and the eye velocity and acceleration traces were obtained using a two-point forward difference algorithm to identify saccadic eye movements. Eye movement records were segmented into the blink, the saccade, and the fixation periods. Further details are described in Supplementary Methods.

Eye Movement Paradigms and Extracted Measurements

We administered 3 eye movement paradigms (free-viewing test, fixation stability test, and smooth pursuit test) and obtained 35 eye movement measurements comprising 13 measurements from the free viewing test, 16 measurements from the smooth pursuit test, and 6 measurements from the fixation stability test. We chose the examinations of eye movements used in the previously published reports (18, 36, 37). Examples of eye movement examinations are shown in Figure 1. Each paradigm is discussed in detail below.

The free-viewing test was performed using images from five categories that involved buildings, everyday items, foods, fractal patterns, and noise (four images for each category). The subjects were instructed to freely view the presented image for 8 s (Figure 1A). We measured the number and the median duration of the fixations, the number of saccades, the median durations, the amplitude, the mean and the peak velocity of saccades, the scanpath length, and the fixation density (38). The medians over each image were calculated for each eye movement measurement. In addition, we examined the main sequence relation of the saccades of individual subjects (for details, see Supplementary Methods).

In the smooth pursuit eye movement test, subjects were required to track a moving target for 20 s. The target moved horizontally and vertically with a Lissajous trajectory (Figure 1B) and the trial was repeated twice. We measured the number and the median duration of fixations, along with the number, median...
duration, amplitude, mean, and peak velocities of saccades. In addition, we measured the position gain, the velocity gain, the common logarithm of the signal-to-noise ratio (SNR), and the root mean square error (RMSE) for the horizontal and vertical eye movements separately in each trial.

For the fixation stability test, subjects were required to maintain their gaze on a fixed target presented at the center of the monitor (Figure 1C). A few seconds (1–2 s randomly) after the central fixed target was continually presented, a distracter stimulus appeared at 3◦ right or left of the central fixed target and presented for 5 s. We measured the number of fixations, the median duration of fixations, the number of saccades, the number of microsaccades, and the scanpath length for each trial. The trial was repeated four times, and we calculated the mean of each eye movement measure over all the trials.

Because some eye movement measurements are influenced by optical devices (39), we divided subjects into naked eye, glasses, and soft contact lens groups and normalized the measurements. Z-scores are dimensionless mathematical tools that allow for the mean-normalization of results within groups. Z-scores are standardized scores (by the group mean and group standard deviation) and no normal assumption is made. They indicate how many standard deviations (σ) an observation (X) is above or below the mean of a control group (µ).

\[ z = \frac{X - \mu}{\sigma}, \]

where X represents individual data for the observed measurement and µ and σ represent the mean and the standard deviation for the control group, respectively.

**Statistical Analysis**

All statistical analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA). Group comparisons of demographic variables were performed using a two-tailed t-test or a χ²-test when appropriate.

Because we previously reported that age should be considered when investigating eye movements (40) and other studies also indicated significant effects of age on saccadic eye movements and smooth pursuit eye movements (41, 42), we performed analyses of covariance (ANCOVAs) with the group factor as an independent variable and age as a covariate for z score of each eye measurement. We performed a correction with a false discovery rate (FDR) of 0.05 (Benjamini–Hochberg procedure) for each measurement, considering the nature of multiple comparisons. When significant group-by-age interactions were observed, to evaluate the age effect, we divided MDD and HCs into two cohorts (younger and older cohorts) stratified by the median age of MDD, 48 years [HC group: younger cohort (N = 314), older cohort (N = 86); MDD group: younger cohort (N = 19), older cohort (N = 18)]. Then, we examined the simple main effects of group in younger and older cohorts using a general linear model.

For associations between eye movement measurements and demographics, we conducted multiple regression analyses using the stepwise method with eye movement measurements, which showed a significant difference between groups, where eye movement measurements were dependent variables, and age, medication (CPZ, DZP, and IMP equivalents), and HAM-D scores were independent variables. The significance level was set at \( p < 0.05 \).

A linear discriminant analysis was performed using statistically significant measurements as independent valuables between groups. After the discriminant analysis, the discriminant score was calculated. Optimal sensitivity and specificity of the discriminant score to differentiate between MDD and HCs were determined via receiver operating characteristic (ROC) curve analysis using a non-parametric approach. We calculated the Youden index for each cutoff value \([\text{Sensitivity} + \text{Specificity}) – 1]\) to find the cutoff values that maximized the discriminating power.

In addition, 37 HCs were randomly selected to match ages between groups by a technician who was unrelated to this study, and we performed t-tests to evaluate age-matched group differences in eye movement measurements. A linear discriminant analysis was also performed.
### TABLE 3 | Results of ANCOVA.

|                         | HCs (n = 400) | MDD (n = 37) | Age-by-group interaction | Effect of group |
|-------------------------|---------------|--------------|---------------------------|----------------|
|                         | Median        | SD           | Median                    | SD             | df | F-value | p-value | F-value | p-value |
| **Free-viewing test**   |               |              |                           |                |
| Number of fixations     | 23.00         | 3.32         | 21.50                     | 4.93           | 1,433 | 5.07    | 2.5 × 10^{-2} | N/A   | N/A     |
| Duration of fixation    | 254.50        | 46.30        | 267.00                    | 86.41          | 1,433 | 5.51    | 1.9 × 10^{-2} | N/A   | N/A     |
| Number of saccades      | 21.00         | 3.80         | 20.00                     | 5.33           | 1,433 | 7.19    | 7.6 × 10^{-3} | N/A   | N/A     |
| Duration of saccades    | 42.38         | 5.59         | 42.50                     | 6.65           | 1,433 | 0.10    | 0.75    | 0.91    | 0.34    |
| Saccade amplitude       | 4.00          | 1.17         | 3.60                      | 0.99           | 1,433 | 0.00    | 0.99    | 0.66    | 0.42    |
| Average saccade velocity| 93.94         | 19.25        | 81.99                     | 17.50          | 1,433 | 0.12    | 0.73    | 2.51    | 0.11    |
| Peak saccade velocity   | 185.10        | 44.55        | 181.81                    | 43.85          | 1,433 | 0.73    | 0.39    | 0.01    | 0.91    |
| Scanpath length         | 110.70        | 28.81        | 92.56                     | 34.98          | 1,433 | 2.19    | 0.14    | 8.30    | 4.2 × 10^{-3} |
| Fixation density        | 0.88          | 0.39         | 0.92                      | 0.51           | 1,433 | 9.58    | 2.1 × 10^{-3} | N/A   | N/A     |
| **Smooth pursuit test** |               |              |                           |                |
| Horizontal SNR          | 2.03          | 0.16         | 2.02                      | 0.18           | 1,433 | 2.74    | 0.10    | 0.00    | 0.95    |
| Horizontal position gain| 1.01          | 0.03         | 1.00                      | 0.03           | 1,433 | 0.93    | 0.33    | 0.34    | 0.56    |
| Horizontal RMSE         | 8.35          | 4.18         | 8.78                      | 4.11           | 1,433 | 2.30    | 0.13    | 0.39    | 0.53    |
| Vertical SNR            | 1.84          | 0.20         | 1.80                      | 0.20           | 1,433 | 1.22    | 0.27    | 0.27    | 0.60    |
| Vertical position gain  | 0.96          | 0.07         | 0.95                      | 0.09           | 1,433 | 0.67    | 0.41    | 1.18    | 0.28    |
| Vertical RMSE           | 14.03         | 7.94         | 13.83                     | 9.69           | 1,433 | 1.56    | 0.21    | 0.15    | 0.70    |
| Number of fixations     | 58.25         | 13.77        | 60.00                     | 13.99          | 1,433 | 0.17    | 0.68    | 1.00    | 0.32    |
| Duration of fixations   | 259.88        | 69.00        | 250.75                    | 79.92          | 1,433 | 1.29    | 0.26    | 4.27    | 0.04    |
| Number of saccades      | 56.00         | 15.71        | 59.50                     | 13.85          | 1,433 | 0.16    | 0.69    | 0.73    | 0.39    |
| Duration of saccades    | 30.13         | 5.63         | 34.50                     | 9.41           | 1,433 | 3.62    | 0.06    | 8.54    | 3.7 × 10^{-3} |
| Saccade amplitude       | 1.94          | 0.62         | 2.38                      | 0.71           | 1,433 | 3.22    | 0.07    | 5.40    | 0.02    |
| Average saccade velocity| 65.13         | 11.71        | 70.80                     | 9.85           | 1,433 | 0.00    | 0.96    | 1.42    | 0.23    |
| Peak saccade velocity   | 98.05         | 38.71        | 136.46                    | 46.52          | 1,433 | 2.32    | 0.13    | 8.41    | 3.9 × 10^{-3} |
| Horizontal velocity gain| 0.85          | 0.11         | 0.77                      | 0.14           | 1,433 | 0.85    | 0.36    | 4.60    | 0.03    |
| Vertical velocity gain  | 0.76          | 0.13         | 0.70                      | 0.16           | 1,433 | 0.59    | 0.44    | 1.43    | 0.23    |
| Number of blinks        | 1.00          | 4.00         | 1.00                      | 1.31           | 1,433 | 3.64    | 0.06    | 0.45    | 0.50    |
| **Fixation stability test** |            |              |                           |                |
| Number of fixations     | 3.00          | 2.46         | 3.25                      | 2.71           | 1,433 | 0.25    | 0.62    | 0.10    | 0.75    |
| Duration of fixation    | 2057.19       | 1492.87      | 1422.50                   | 1538.35        | 1,433 | 0.21    | 0.64    | 0.50    | 0.48    |
| Number of saccades      | 1.50          | 2.30         | 2.00                      | 2.53           | 1,433 | 0.91    | 0.34    | 0.04    | 0.85    |
| Scanpath length         | 1.13          | 2.21         | 1.36                      | 2.43           | 1,433 | 0.23    | 0.63    | 0.02    | 0.89    |
| Number of microsaccades | 6.25          | 3.51         | 6.50                      | 4.17           | 1,433 | 0.46    | 0.50    | 0.13    | 0.72    |
| Number of blinks        | 0.00          | 0.97         | 0.00                      | 0.70           | 1,433 | 2.68    | 0.10    | 0.04    | 0.84    |

RMSE, Root mean square error; SNR, signal-to-noise ratio; N/A, not applicable.

*Represents significant after false discovery rate correction.

---

**RESULTS**

**Demographics and Eye Movement Measurements**

The demographics of both groups are shown in Table 2. There was no difference in the sex ratio between the two groups ($p = 0.85$) or years of education ($p = 0.41$); however, age was significantly different ($p = 8.6 \times 10^{-9}$).

Overall, 35 eye movement measurements were obtained in this study. In the HC group, 189 subjects were naked eyes, 124 wore glasses, and 87 had soft contact lenses, whereas 20, 14, and 3 were naked eyes, wore glasses, or had soft contact lenses in the MDD group, respectively (Supplementary Table 1).
Table 3 shows the mean ± SD of 35 measurements for both groups. In the free-viewing test, there was a significant group difference in scanpath length \( F(1, 433) = 8.3, p = 4.2 \times 10^{-3} \) but the other measurements were not significantly different \((0.11 < p < 0.94)\). In the smooth pursuit test, there were significant group differences in duration of saccades \( F(1, 433) = 8.5, p = 3.7 \times 10^{-3} \) and peak saccade velocity \( F(1, 433) = 8.4, p = 3.9 \times 10^{-3} \) but the other measurements were not significantly different \((0.02 < p < 0.95)\). There were no significant group differences in the fixation stability test \((0.48 < p < 0.89)\).

Differences in Younger and Older Cohorts

In 4 out of 35 measurements, there were significant interactions between age and group \( F(1, 433) = 5.1, p = 2.5 \times 10^{-2} \) for number of fixations; \( F(1, 433) = 5.5, p = 1.9 \times 10^{-2} \) for duration of fixation; \( F(1, 433) = 7.2, p = 7.6 \times 10^{-3} \) for number of saccades; and \( F(1, 433) = 9.6, p = 2.1 \times 10^{-3} \) for fixation density (Table 3). For the number of fixations, the group effect was significant in the older cohort \( F(1, 433) = 17.8, p = 2.9 \times 10^{-5} \) but not in the younger cohort \( F(1, 433) = 1.3, p = 0.26 \). For the duration of fixation, the group effect was also significant in the older cohort \( F(1, 433) = 30.7, p = 5.3 \times 10^{-8} \) but not in the younger cohort \( F(1, 433) = 0.19, p = 0.67 \). For the number of saccades, the group effect was significant in the older cohort \( F(1, 433) = 15.0, p = 1.2 \times 10^{-4} \) but not in the younger cohort \( F(1, 433) = 2.4, p = 0.12 \). Finally, for the fixation density, the group effect was significant in the older cohort \( F(1, 433) = 12.4, p = 4.8 \times 10^{-4} \) but not the younger cohort \( F(1, 433) = 1.3, p = 0.26 \), which suggests altered aging effects in MDD (Figure 2).

Correlations Between Eye Movement Measurements and Demographics

No correlations were statistically significant with scanpath length in the free-viewing test. The duration of saccades and peak saccade velocity in the smooth pursuit test had no correlations other than age \((R = 0.44, p = 0.02, R = 0.47, p = 0.01)\), respectively.

**Differences Between Groups**

**Table 3** shows the mean ± SD of 35 measurements for both groups. In the free-viewing test, there was a significant group difference in scanpath length \( F(1, 433) = 8.3, p = 4.2 \times 10^{-3} \) but the other measurements were not significantly different \((0.11 < p < 0.94)\). In the smooth pursuit test, there were significant group differences in duration of saccades \( F(1, 433) = 8.5, p = 3.7 \times 10^{-3} \) and peak saccade velocity \( F(1, 433) = 8.4, p = 3.9 \times 10^{-3} \) but the other measurements were not significantly different \((0.02 < p < 0.95)\). There were no significant group differences in the fixation stability test \((0.48 < p < 0.89)\).

**Discriminant Analysis and ROC Analysis**

Significant group differences were observed in scanpath length in the free-viewing test, and duration of saccades and peak saccade velocity in the smooth pursuit test. We selected scanpath length of the free-viewing test and peak saccade velocity of the smooth pursuit test for the discriminant analysis using z score for each parameter, because these values were statistically significant between groups and were obtained by independent tests. According to the linear discriminant analysis, we correctly classified 72.1% of the subjects using the resubstitution method and correctly classified 71.9% of the subjects using the leave-one-out cross-validation method. The discriminant score was calculated using the following formula: discriminant score = \(-0.52 \times (z \text{ score of scanpath length}) + 0.83 \times (z \text{ score of peak saccade velocity})\). Figure 3 shows the ROC curve of the discriminant score between the MDD and HC groups. The area under the curve (AUC) of the ROC analysis in MDD vs. HCs was 0.76 (standard error = 0.05, \( p = 1.2 \times 10^{-7} \), 95% CI = 0.67 – 0.85), indicating that the discriminant score for the scanpath length in the free-viewing test and the peak saccade velocity in the smooth pursuit test could be used to differentiate between MDD and HC subjects with moderate accuracy. The Youden index indicated a favorable cutoff point of 0.39, which resulted in 81% sensitivity and 69% specificity.

**Age-Matched Group Analysis**

The results of the t-test are shown in Supplementary Table 2. These were: the scanpath length for the free viewing test \((r = 0.61, d = 0.6)\); the duration of saccades and peak saccade velocity for the smooth pursuit test \((r = 3.9 \times 10^{-3}, d = -0.7); r = 1.5 \times 10^{-3}, d = -0.8)\), respectively, but none of them were significant after FDR correction. According to the linear discriminant analysis, we correctly classified 75.7% of the subjects using the resubstitution method and correctly classified 73.0% of the subjects using the leave-one-out cross-validation method. The discriminant score was calculated using the following formula: discriminant score = \(-0.63 \times (\text{scanpath length}) + 0.80 \times (\text{peak saccade velocity})\). Supplementary Figure 1 shows the ROC curve of the discriminant score between the MDD and HC groups in age-matched group analysis. AUC of the ROC analysis in MDD vs.
HCs was 0.77 (standard error = 0.06, $p = 6.5 \times 10^{-5}$, 95% CI = 0.66 – 0.88). The Youden index indicated a favorable cutoff point of 0.03, which resulted in 73% sensitivity and 81% specificity.

**DISCUSSION**

The present study investigated eye movement measurements of MDD using free-viewing, fixation stability, and smooth pursuit tests. The results are as follows: (1) MDD showed a significantly shortened scanpath length in the free-viewing test and a longer duration of saccades and higher peak saccade velocity in the smooth pursuit test compared with HCs; (2) altered aging effects of MDD were observed for the number of fixations, duration of fixation, number of saccades, and fixation density; and (3) the AUC of the ROC analysis was 0.76 (standard error = 0.05, $p = 1.2 \times 10^{-7}$, 95% CI = 0.67 – 0.85).

The current findings are partially consistent with a previous study (31) that reported MDD patients exhibited fewer saccades and a shortened scanpath length in the free-viewing task compared with HCs. In addition, they found that MDD patients had a significantly shorter gaze time and more saccades in the fixation stability test between groups, suggesting that oculomotor impulsivity was not observed in MDD. However, differences in experimental design may account for the reported discrepancies.

Our previous study (20) reported that during the free-viewing test, patients with SZ also had a significantly shortened scanpath length compared with HCs. Based on this result, it appears that the decline in the scanpath length in MDD may be less severe than that in SZ. Egaña et al. (44) reported significant shortened scanpath in SZ compared with HCs was resulted from the increasing occurrence of undetected microsaccades. Our future study will examine this issue for shortened scanpath length in MDD. In the smooth pursuit test, there were significant declines in horizontal and vertical position gains in SZ, but there were no significant changes in position gain in MDD. However, there were significant differences in the duration of saccades and peak saccade velocity, which may indicate that patients with MDD compensate with position error by catch-up saccade. It will be necessary to clarify the commonality and heterogeneity of eye movement parameters in psychiatric disorders in future studies.

Altered aging effects of MDD including the number of fixations, duration of fixation, number of saccades, and fixation density are also of particular interest. Indeed, accelerated brain aging was reported in MDD patients (45). In terms of symptoms, Dunlop et al. (46) suggested that accelerated aging was associated with greater impulsivity and depression severity. A genetic study by Han et al. reported that patients with MDD had a degree of epigenetic and methylation change that was reflective of an older age. In particular, they suggested that MDD patients were 8 months biologically older than people without MDD (47). The current finding on different patterns of aging effects between MDD and HCs suggests that MDD patients may show different age-related changes from HCs, which could relate to disease characteristics. We hope to confirm these findings in a larger cohort in the future.

The results of discriminant analysis and ROC analysis suggest that the combination of scanpath length by free-viewing test and peak saccade velocity by smooth pursuit test are potential biomarkers to differentiate between MDD and HCs. In the present study, we also performed age-matched group analysis and found no significant differences after FDR correction in the eye movement variables that were significantly different in the main ANCOVA. However, in terms of effect sizes comparing MDD and HCs, the impacts of eye movements seem to be more significant compared to other indices. For example, in a structural brain imaging study with mega-analysis methods (48), patients with MDD had a significantly thinner cortical gray matter in the orbitofrontal cortex, anterior cingulate gyrus, posterior cingulate gyrus, insula, and temporal lobes compared to HCs (Cohen’s $d$ effect size: $-0.10$ to $-0.25$).
whereas the effect sizes of our present study were 0.60–0.77. In addition, the study using MRI as a biomarker reported that patients with MDD were distinguished from HCs with a sensitivity of 77% and specificity of 78% (49), which was comparable to the present results. Therefore, it may be reasonable to select variables of eye movements as potential biomarkers. It will be important to utilize the same measurements for the differentiation of other psychiatric disorders. Further study of the eye movement measurements in psychiatric disorders other than SZ and MDD, such as bipolar disorder, anxiety disorder, obsessive-compulsive disorder, and autism spectrum disorder may identify eye movement-related biological differences across psychiatric disorders. In future clinical applications, it may be necessary to narrow down the parameters to be used.

Several limitations of this study must be considered. First, differences in group age might have influenced the discrimination analysis because we used the peak saccade velocity in the smooth pursuit test as an independent variable, which is associated with age. To obtain more accurate results, demographically-matched groups should be used in future analyses. Second, patients with MDD had various disease status including mild-to-moderate severity and remission with medication. Furthermore, the sample size was relatively small. Thus, larger numbers of samples with all types of depressive states ranging from mild to severe will be required to determine whether the abnormalities are traits or a state of the disorder. As shown in age-matched group analyses, although the effect sizes were large, significant differences would only be found with larger sample sizes in an exploratory study. Therefore, we need to confirm further our results in another extensive age-matched data set as a confirmatory study. Third, the current study cannot answer the question of whether the current findings are specific to MDD or not. It will thus be important to investigate other psychiatric disorders such as bipolar disorder. Our future study will perform direct comparisons among disorders, including schizophrenia, with larger sample size. Finally, the neural basis of these age-related eye-movement abnormal changes remains poorly understood. Thus, to determine the neural basis of these age-related eye-movement abnormalities, functional neuroimaging studies including functional magnetic resonance imaging, electroencephalography, or magnetoencephalography should be combined during the eye-movement tasks.

CONCLUSION

In the current study, MDD patients had a significantly shortened scanpath length in the free-viewing test and a longer duration of saccades and higher peak saccade velocity in the smooth pursuit test compared with HCs. In addition, altered aging effects of MDD were detected for the number of fixations, duration of fixation, number of saccades, and fixation density. The discriminant score calculated by the scanpath length in the free-viewing test and peak saccade velocity in the smooth pursuit test might be used to differentiate between MDD and HCs with moderate accuracy. These results suggest that detailed eye movement tests can assist in differentiating MDD from HCs, especially in older subjects.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Research Ethical Committees of Kyushu University, Osaka University, The University of Tokyo, Nagoya University, and Nara Medical University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JT, KMi, RH, YH, and TO designed the study. JT, KMi, KMo, MF, HY, YY, NK, ES, KO, and TS collected and analyzed the data. JT prepared the first draft of the manuscript and created the figures. KMi, YH, RH, and TO assisted with data analyses and supervised the research. KMi, KMo, MF, HY, YY, NK, ES, KO, TS, TN, KK, RH, and TO edited the manuscript. All authors contributed to and have approved the final manuscript.

FUNDING

This research was supported, in part, by the Japan Agency for Medical Research and Development under grant numbers JP21dm0207069 (TO, KK, and KMi) and GAJ1020620 (JP19dm0107124h0004) (YH), JP18dm0207066 (RH), JP20dm0307002 (RH), JP20lm0203007 (RH); a Grant-in-Aid for Young Scientists B JP22791129 (YH); a Grant-in-Aid for Scientific Research C: JP 16K10217 (TO), JP 15K09836 (YH), JP 18K07604 (YH), JP 19H03579 (YH), B: 20H03611 (RH) and Fund for the Promotion of Joint International Research (Fostering Joint International Research B): JP20KK0193 (YH) from the Japan Society for the Promotion of Science; Medical Research Fund (YH) from Takeda Science Foundation; Research Fund Award (YH) from the Brain Science Foundation; 60th Research Grant Award (YH) from UBE Industries Foundation; SIRS Research Fund Award (YH) from the Schizophrenia International Research Society and The Grand Prize Young Investigator Program Award 2020 (YH) from the Japanese Society of Biological Psychiatry. This work was supported in part by UTokyo Center for Integrative Science of Human Behavior (CiSHuB), and by the International Research Center for Neurointelligence (WPI-IRCN) at The University of Tokyo Institutes for Advanced Study (UTIAS) (KK). The funding sources had no further role in study design, in the collection, analysis, interpretation of data, in
writing the report, or in the decision to submit the paper for publication.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the administrative support of Motoko Soya and Maiko Kawasoe. We thank J. Ludovic Croxford, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.

REFERENCES

1. World Health Organization. Depression. (2020). Available online at: https://www.who.int/news-room/fact-sheets/detail/depression
2. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization (2017). Available online at: https://apps.who.int/iris/handle/10665/254610
3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1789–858. doi: 10.1016/S0140-6736(18)32279-7
4. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. (2012) 379:1045–55. doi: 10.1016/S0140-6736(11)60602-8
5. Boku S, Nakagawa S, Toda H, Hishimoto A. Neural basis of major depressive disorder: beyond monoamine hypothesis. Psychiatry Clin Neurosci. (2018) 72:3–12. doi: 10.1111/pcn.12604
6. Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. (2019) 73:613–27. doi: 10.1111/pcn.12902
7. North CS, Baron D, Chen AF. Prevalence and predictors of postdisaster major depression: convergence of evidence from 11 disaster studies using consistent methods. J Psychiatr Res. (2018) 102:96–101. doi: 10.1016/j.jpsychires.2017.12.013
8. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. (2021) 8:130–40. doi: 10.1016/S2215-3326(20)30462-4
9. Shigemura J, Ursano RJ, Morganstein JC, Kurosawa M, Benedek DM. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: mental health consequences and target populations. Psychiatry Clin Neurosci. (2020) 74:281–2. doi: 10.1111/pcn.12988
10. Stavrídua A, Stergiopoulos AA, Panagouli E, Mésiris G, Thirios A, Mougiakos T, et al. Psychosocial consequences of COVID-19 in children, adolescents and young adults: a systematic review. Psychiatry Clin Neurosci. (2020) 74:615–6. doi: 10.1111/pcn.13134
11. Kashihara J, Yamakawa I, Kameyama A, Muranaka M, Taku K, Sakamoto S. Perceptions of traditional and modern types of depression: a cross-cultural vignette survey comparing Japanese and American undergraduate students. Psychiatry Clin Neurosci. (2019) 73:441–7. doi: 10.1111/pcn.12838
12. Kobayashi D, First MB, Shimbo T, Kanba S, Hirano Y. Association of self-reported religiosity with the development of major depression in multireligious country Japan. Psychiatry Clin Neurosci. (2020) 74:535–41. doi: 10.1111/pcn.13087
13. Scalabrini A, Xu J, Northoff G. What COVID-19 tells us about the self: the deep intersubjective and cultural layers of our brain. Psychiatry Clin Neurosci. (2021) 75:37–45. doi: 10.1111/pcn.13185
14. Fekadu N, Shibeshi W, Engidawork E. Major depressive disorder: pathophysiology and clinical management. J Depress Anxiety. (2017) 6:255. doi: 10.4172/2167-1044.1000255
15. Osorio FL, Loureiro SR, Hallack JEC, Machado-de-Sousa JP, Ushirohira JM, Baes CVW, et al. Clinical validity and intrarater and test-retest reliability of the Structured Clinical Interview for DSM-5 - Clinician Version (SCID-5-CV). Psychiatry Clin Neurosci. (2019) 73:754–60. doi: 10.1111/pcn.12931
16. Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. J Clin Psychiatry. (2018) 79:17m11765. doi: 10.4088/JCP.17m11765
17. Goldberg JF, Nierenberg AA, Iosifescu DV. Wrestling with antidepressant use in bipolar disorder: the ongoing debate. J Clin Psychiatry. (2021) 82:19ac13181. doi: 10.4088/JCP.19ac13181
18. Benson PJ, Beedie SA, Shephard E, Giegling I, Rujescu D, St Clair D. Simple viewing tests can detect eye movement abnormalities that distinguish schizophrenia cases from controls with exceptional accuracy. Biol Psychiatry. (2012) 72:716–24. doi: 10.1016/j.biopsych.2012.04.019
19. Brakemeier S, Sprenger A, Meyhoff I, McDowell JE, Rubin LH, Hill SK, et al. Smooth pursuit eye movement deficits as a biomarker for psychotic features in bipolar disorder: Findings from the PARDIS study. Bipolar Disord. (2020) 22:602–11. doi: 10.1111/bdi.12865
20. Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Iwase M, et al. Eye movement as a biomarker of schizophrenia: using an integrated eye movement score. Psychiatry Clin Neurosci. (2017) 71:104–14. doi: 10.1111/pcn.12460
21. Wolf A, Ueda K, Hirano Y. Recent updates of eye movement abnormalities in patients with schizophrenia: a scoping review. Psychiatry Clin Neurosci. (2021) 75:82–100. doi: 10.1111/pcn.13188
22. Hashimoto R. Do eye movement abnormalities in schizophrenia cause Prazexor Gefühl? Psychiatry Clin Neurosci. (2021) 75:79–80. doi: 10.1111/pcn.13197
23. Smyrnis N, Amado I, Krebs MO, Sweeney JA. Eye movements in psychiatry. In: Klein C, Ettinger U, editors. Eye Movement Research. Studies in Neuroscience, Psychology and Behavioral Economics. Cham: Springer (2019). p. 703–48. doi: 10.1007/978-3-030-20885-3_16
24. Iacono WG, Altmann PS, Ramchandani P, Jones J, Vernescu A. Risk factors associated with antidepressant use in bipolar disorder: the ongoing debate. J Alzheimers Dis. (2012) 39:355–44. doi: 10.3231/84Ax.91.1.35
25. Abi LA, Friedman L, Jesberger J, Malki A, Meltzer HY. Quantitative assessment of smooth pursuit gain and catch-up saccades in schizophrenia and affective disorders. Biol Psychiatry. (1991) 29:1063–72. doi: 10.1016/0006-3223(91)90248-K
26. Malaspina D, Amador XF, Coleman EA, Mayr TL, Friedman JH, Sackeim HA. Smooth pursuit eye movement abnormality in severe major depression: effects of ECT and clinical recovery. J Neuropsychiatry Clin Neurosci. (1994) 6:36–42.
27. Flechner KM, Steinacher B, Sauer R, Mackert A. Smooth pursuit eye movements in schizophrenia and affective disorder. Psychol Med. (1997) 27:1411–9. doi: 10.1017/S0033291797005799
28. Flechner KM, Steinacher B, Sauer R, Mackert A. Smooth pursuit eye movements of patients with schizophrenia and affective disorder during

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.673443/full#supplementary-material

Supplementary Figure 1 | Receiver-operator curve (ROC) to predict patients with major depressive disorder. Area under the ROC = 0.77 (standard error = 0.06, p = 6.5 × 10−5, 95% confidence interval, 0.66–0.88).

Supplementary Table 1 | Eye movement measurements of HCs and MDD subjects.

Supplementary Table 2 | Results of t-tests between age-matched groups.
clinical treatment. *Eur Arch Psychiatry Clin Neurosci.* (2002) 252:49–53. doi: 10.1007/s004060200011

29. Fabisch K, Fitz W, Fabisch H, Haas-Krammer A, Klug G, Zapotoczky S, et al. Sinusoidal smooth pursuit eye tracking at different stimulus frequencies: position error and velocity error before catch-up saccades in schizophrenia and in major depressive disorder. *Aust N Z J Psychiatry.* (2009) 43:855–65. doi: 10.1080/00048670903107542

30. Chen S, Zhou R, Cui H, Chen X. Deficits in cue detection underlie event-based prospective memory impairment in major depression: an eye tracking study. *Psychiatry Res.* (2013) 209:453–8. doi: 10.1016/j.psychres.2013.01.015

31. Li Y, Xu Y, Xia M, Zhang T, Wang J, Liu X, et al. Eye movement indices in the study of depressive disorder. *Shanghai Arch Psychiatry.* (2016) 28:326–34.

32. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry.* (1960) 23:56–62. doi: 10.1136/jnnp.23.1.56

33. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. *Psychiatry Clin Neurosci.* (2015) 69:440–7. doi: 10.1111/jpcn.12275

34. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. *J Affect Disord.* (2013) 150:384–8. doi: 10.1016/j.jad.2013.04.028

35. Brainard DH. The psychophysics toolbox. *Spat Vis.* (1997) 10:433–6. doi: 10.1163/156856897X00357

36. Miura K, Hashimoto R, Fujimoto M, Yamamori H, Yasuda Y, Ohi K, et al. An integrated eye movement score as a neurophysiological marker of schizophrenia. *Schizophr Res.* (2014) 160:228–9. doi: 10.3758/s00283-014-0234-z

37. Arolt V, Teichert HM, Steege D, Lencer R, Heide W. Distinquishing schizophrenic patients from healthy controls by quantitative measurement of eye movement para-meters. *Biol Psychiatry.* (1998) 44:448–58. doi: 10.1016/S0006-3223(97)00479-4

38. Over EA, Hooge IT, Erkelens CJ. A quantitative measure for the uniformity of fixation density: the Voronoi method. *Behav Res Methods.* (2006) 38:251–61. doi: 10.3758/BF03192777

39. Müller C, Stoll W, Schmal F. The effect of optical devices and repeated trials on the velocity of saccadic eye movements. *Acta Otolaryngol.* (2003) 123:471–6. doi: 10.1080/00016480300684

40. Takahashi J, Miura K, Morita K, Fujimoto M, Miyata S, Okazaki K, et al. Effects of age and sex on eye movement characteristics. *Neuropsychopharmacol Rep.* (2021) 41:152–8. doi: 10.1002/npr2.12163

41. Irving EL, Steinbach MJ, Lillakas L, Babu RJ, Hutchings N. Horizontal saccade dynamics across the human life span. *Invest Ophthalmol Vis Sci.* (2006) 47:2478–84. doi: 10.1167/iovs.05-1311

42. de Hemptinne C, Ivanou I, Lefèvre P, Missal M. How does Parkinson’s disease and aging affect temporal expectation and the implicit timing of eye movements? *Neuropsychologia.* (2013) 51:340–8. doi: 10.1016/j.neuropsychologia.2012.10.001

43. Hsu TY, Lee HC, Lane TJ, Missal M. Temporal preparation, impulsivity and short-term memory in depression. *Front Behav Neurosci.* (2019) 13:258. doi: 10.3389/fnbeh.2019.00258

44. Egaña JI, Devia C, Mayol R, Parrini J, Orellana G, Ruiz A, et al. Small saccades and image complexity during free viewing of natural images in schizophrenia. *Front Psychiatry.* (2013) 4:1–13. doi: 10.3389/fpsyt.2013.00037

45. Wolkowitz OM, Epel ES, Reus VL, Mellon SH. Depression gets old fast: do stress and depression accelerate cell aging? *Depress Anxiety.* (2010) 27:327–38. doi: 10.1002/da.20686

46. Dunlop K, Victoria LW, Downar J, Gunnung FM, Liston C. Accelerated brain aging predicts impulsivity and symptom severity in depression. *Neuropsychopharmacology.* (2021) 46:911–19. doi: 10.1038/s41386-021-00967-x

47. Han LKM, Aghajani M, Clark SL, Chan RF, Hattab MW, Shabalin AA, et al. Epigenetic aging in major depressive disorder. *Am J Psychiatry.* (2018) 175:774–82. doi: 10.1176/appi.ajp.2018.17060595

48. Schmaal L, Hibar DP, Sämann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. *Mol Psychiatry.* (2017) 22:900–9. doi: 10.1038/mp.2016.60

49. Kambeitz J, Cabral C, Sacchet MD, Gotlib IH, Zahn R, Serpa MH, et al. Detecting neuroimaging biomarkers for depression: a meta-analysis of multivariate pattern recognition studies. *Biol Psychiatry.* (2017) 82:330–8. doi: 10.1016/j.biopsych.2016.10.028

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Takahashi, Hirano, Miura, Morita, Fujimoto, Yamamori, Yasuda, Kudo, Shishido, Okazaki, Shinno, Nakao, Kasai, Hashimoto and Onitsuka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.